頭頸部癌に対するFT-207経口投与の経験

SOME EXPERIENCE IN PER-ORAL ADMINISTRATION OF FT-207 IN THE TREATMENT OF THE HEAD AND NECK CANCERS

　I．はじめに

　5-FuはBleomycinとともに今日頭頸部悪性腫瘍の化学療法剤として広く使用されている。1966年ソ連のHillerら^1）によつて合成された5-Fuの誘導体，N₁-（'2-tetrahydrofuryl）-5-fluorouracil（以下FT-207と略記）は毒性が低く，血中持続時間が長いことなど従来の5-Fuとは異なつた利点も証明されている。

　抗癌剤の投与法として頭頸部領域では動脈内投与がもつとも有効であることは既によく知られている事実であるが，FT-207の如く経口投与が可能な薬剤は使用法が簡便である点に特徴があり，その効力についてはわれわれ臨床家が関心をもつところである。今回われわれは頭頸部悪性腫瘍患者に対し本剤の経口投与を試みたのでその成績について報告する。

　By per-oral administration of FT-207 for treatment of the head and neck cancers, a study was made as to the degree in which the drug may be disseminated in the region.

　Clinically, the effectivity of this drug was good in 11 out of 17 cases treated and ineffective in 6 cases. Among the 11 cases considered effective 8 were concomitantly treated by X-ray therapy while, the remaining 3 was treated by drug administration alone.

　As to the amount of tissue dissemination the FT-207 by mouth it was 0.256 to 0.725 mc/g and as compared to the intraarterial administration of 5 Fu, the shadow produced in the X-ray film appeared to be less prominent, but the lasting-time of the drug within the tissues was longer.

　In general the per-oral administration of the drug appeared to be more appropriate.